Microwave-assisted synthesis and regioisomeric structural elucidation of novel benzimidazo[1,2-d][1,4]benzodiazepinone derivatives

David Pessoa-Mahana, a* Christian Espinosa-Bustos, a Jaime Mella-Raipán, a Jorge Canales-Pacheco, a and Hernan Pessoa-Mahanab

a Pharmacy Department, Faculty of Chemistry, Pontificia Universidad Catolica de Chile, P.O.Box 306, 22, Santiago, Chile
b Department of Organic and Physical Chemistry, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, P.O.Box 233, Santiago, Chile
E-mail: cpessoa@uc.cl

Abstract
The synthesis of 5H-benzimidazo [1,2-d][1,4] benzodiazepin-6(7H)-ones 3a-e from readily available 2-(2-aminophenyl)-1H-benzo[d]imidazole derivatives 2a-e and 2-bromoacetyl bromide under microwave conditions is described. Unambiguous structural elucidation of the obtained regioisomers was finally established by means of 2D-NOESY experiment.

Keywords: Heterocycles, benzimidazoles, benzodiazepines, microwaves

Introduction

Seven-membered heterocyclic ring represents an area of considerable interest mainly due to its interesting pharmacological properties. 1,2 Among them, undoubtedly the [1,4]benzodiazepine skeleton has been one of the most studied, and commonly associated with central nervous system depressive effects. 3 The [1,4] benzodiazepine framework is nowadays linked with antitumoral activity, in such sense pyrrolo[1,4]benzodiazepine B, 4,5 pyrazolo[4,3-e] pyrrolo[1,2-a] [1,4]diazepinone C 6 and dibenzo[b,e][1,4]diazepin-11-one D 7 (Figure 1) have been reported to display cytotoxic activity.
Figure 1. Citotoxic fused 1,4-benzodiazepines A-D reported in literature and target benzimidazo[1,2-d][1,4]benzodiazepinones 3a-e.

On the other hand, the benzimidazole unit is the key building block for a variety of derivatives that are known to play crucial roles in the functions of a number of anticancer, antimicrobial and antiviral compounds among others. However, to the best of our knowledge, there are just a few works reporting the synthesis of benzimidazole rings fused to a [1,4]benzodiazepine framework. Skalitzky and co-workers described the synthesis of 5,6-dihydroimidazo[4,5,1-jk][1,4] benzodiazepin-7(4H)-one derivatives A (Figure 1) with a potent cytotoxic activity.

The benzimidazo-benzodiazepinone framework 3a (R=H) was first reported by Duncan et al. Years later Cherkaoui et al, reported just the isolation of 3a as an intermediate in the route to triazolobenzodiazepine derivatives. This compound was obtained by a condensation reaction between 2-bromoacetyl bromide and 2-(1H-benzimidazol-2-yl) aniline, under drastic heating conditions and long reaction times. As a part of our medicinal chemistry project aimed at the synthesis of potential anticancer agents, we are interested in to extend the studies towards the synthesis of novel 5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives 3a-e under microwave-promoted conditions.

Given that microwave-assisted reactions take place at rates dramatically enhanced over classical heating, providing increased yields and lower side reactions, we therefore decided to probe microwave stimulation as environmentally friendly protocol. The structure of the target compounds have been unequivocally established by 1H NMR, 13C NMR and 2D-ROESY (rotating-frame Overhauser spectroscopy) experiments.

Results and Discussion

The synthesis of 5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-ones 3(a-e) has been accomplished according to the sequence displayed on scheme 1. Equimolar reaction of
commercial substituted o-phenylenediamines with 2-nitrobenzaldehyde in ethanol afforded the corresponding benzimidazoles 1(a-e) in high yields (80% - 90%). Subsequent nitro group reduction of 1(a-e) derivatives was efficiently accomplished using iron powder in a mixture of concentrated HCl, ethanol and water (0.25:1:1), obtaining the corresponding 2-(1H-benzimidazol-2-yl)aniline derivatives 2a-e in good yields (70-80%).

Scheme 1. Reagents and conditions. (a) 2-nitrobenzaldehyde, o-phenylenediamine, ethanol, stirring, rt., 48 H. (b) Iron powder, solution of HCl(concd.):EtOH:H₂O (0.25:1:1) stirring, rt, 15 m. (c) 2-Bromoacetyl bromide, anhydrous THF, Na₂CO₃, microwave (300 W).

The condensation reaction between 2-(1H-benzimidazol-2-yl)aniline derivatives 2a-e and 2-bromoacetyl bromide, was carried under microwave irradiation (300 W) in anhydrous THF and sodium carbonate. The reactions were successfully completed at 1 to 6 minutes when a white precipitated was formed and the presence of a new compound was corroborated by thin layer chromatography.

It should be noted that although benzimidazole precursors 2b-d could exist under two tautomeric forms, only the single obtained benzimidazo benzodiazepine regioisomers 3b-d were obtained. These results suggest that the thermodynamic more stable tautomer will probably determine the course of the reaction. As expected, conformational analysis carried out by ab initio studies on intermediate ii (scheme 2) confirmed the presence of an intramolecular hydrogen bonding between the amide and the NH of the benzimidazole ring.

Besides, the regiochemistry of the nucleophilic attack could yield either the 5H-benzimidazo[1,2-β][1,4]benzodiazepin-6(7H)-ones 3a-e or the 5,6-dihydro-7H-benzimidazo[1,2-β][1,4]benzodiazepin-7-ones 4. However, no mixture of regioisomers was found for final products 3a-3e, as judged by TLC and ¹H NMR. A previous Fukui calculus (DFT at B3LYP level of theory with a set of basis 3-21G) performed in Gaussian assigned a significantly higher nucleophilicity to the aniline in 2a-e compared to the benzimidazole. This suggested that the
obtaining of structure 3a-e is favored over structure 4. In fact, the following spectroscopic observations confirmed this expectation: i) the IR (KBr) spectrum of compounds 3a-e exhibited the typical amidic carbonyl group absorption (1660-1680 cm⁻¹) in accord with amides 3a-e rather than 4. This may be attributed to the low amidic character exhibited by isomer 4; ii) the ¹H NMR of 3a-e derivatives displayed a singlet for one proton in the amidic region (δ= 10.55 -11.01 ppm) and a singlet for two protons at δ= 4.74-5.14 ppm, that can be assigned to NH-5 and to the methylenic protons on C-7, respectively. On the other hand, coupling between the methylene hydrogens and the NH are expected if the structure of compounds was consistent with 4.

More information supporting the proposed structures of compounds 3a-e aroused from a set of two complementary experiments. First, a 2D NOESY experiment clearly showed the presence of a through-space NOE effect between the aromatic H-4 and the NH in 3d, as shown in figure 2. Second, two complementary decoupled 1D ¹H homonuclear spectra for 3d were recorded. When the NH proton (d, 10.67 ppm) was irradiated, the H-4 signal, (dd, 7.49 ppm) collapsed, supporting the NH/H-4 connectivity. Additionally, when the 9-H nucleus was irradiated (s, 7.91 ppm) the 7-CH₂ signal (d, 4.96 ppm) collapsed, supporting the 9-H /7-CH₂ connectivity. All the above theoretical and experimental evidence support the proposed structures 3a-e.

![Figure 2. NOE effects between NH and H4 in a 2D-NOESY experiment.](image)

According to the obtained results, a plausible mechanistic sequence (scheme 2), would involve a nucleophilic attack of the primary amine of the aniline 2 on the acid halide of the 2-bromoacetyl bromide, to give i as an intermediate, which would undergoes a benzimidazolic nitrogen attack, followed by a cyclodehydrobromination, thereby resulting in the 5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-ones 3a-e.
Scheme 2. Probable mechanistic sequence for the obtaining of 5H-benzimidazo[1,2-d][1,4]-benzodiazepin-6(7H)-ones 3a-3.

The fast microwaves-promoted cyclization gave the target compounds in good yields; with reaction times between 1 and 6 minutes (Table 1).

| Compound | Reaction time (min) | Yield (%) |
|----------|---------------------|-----------|
| 3a       | 1                   | 70        |
| 3b       | 6                   | 57        |
| 3c       | 5                   | 55        |
| 3d       | 5                   | 48        |
| 3e       | 2                   | 50        |

As a result, we have developed a rapid, simple microwave-promoted synthesis of novel 5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives. The structures of the obtained regioisomers were deduced and supported from the inspections of complete spectroscopic data.

Experimental Section

General. All organic solvents used for the synthesis were of analytical grade. Melting points were determined on a Stuart Scientific SMP3 apparatus and are uncorrected. IR spectra were recorded on a Brucker Vector 22 spectrophotometer using KBr discs. $^1$H and $^{13}$C NMR spectra were obtained on a Brucker APC-200 spectrometer using tetramethylsilane as internal reference.
Column chromatography was performed on Merck silica gel 60 (70-230 mesh). Thin layer chromatographic separations were performed on Merck Kieselgel 60 (70-230 mesh). Elemental analyses were carried out on a FISONS EA 1108 CHNS-O analyzer. The microwave reactions were carried out in a CEM Discover microwave reactor and irradiated at for the period shown in the table. The reaction temperature was maintained by modulating the power level of the reactor. Yield values are given for pure products.

**General synthetic procedure for 2-(2-nitrophenyl)-1H-benzo[d]imidazole derivatives 1a-e**

A solution of 2-nitrobenzaldehyde (1 equiv.) in ethanol (60 mL) and the corresponding o-phenylenediamine (1 equiv.) is stirred at 80 °C for 24 hours. The reaction mixture is then poured into water. The precipitate is then purified by recrystallization from ethanol, isolating the corresponding benzimidazoles 3(a-e). Compound 1a has been previously described.20

**6-Fluoro-2-(2’-nitrophenyl)-1H-benzo[d]imidazole (1b).** Prepared from 4-fluoro-1,2-phenylenediamine (500 mg, 3.96 mmol) and 2-nitrobenzaldehyde (600 mg, 3.96 mmol). Yield = 75%; mp: 197 – 198 °C (Ethanol); IR (KBr) cm⁻¹: 3207 (NH), 1529(NO₂), 1341(NO₂), 1H NMR (200 MHz, DMSO-d₆) δ: 13.16 (1H, s, NH), 8.05 (dd, 1H, J₁ = 7.8, J₂ = 1.5 H-3’), 7.95 (dd, 1H, J₁ = 7.7, J₂ = 1.6, H-6’), 7.87 (td, 1H, J₁ = 7.5, J₂ = 1.4, H-5’), 7.79 (dd, 1H, J₁ = 7.8, J₂ = 1.7, H-7), 7.63 (m, 1H, H-4’), 7.45 (dd, 1H, J₁ = 8.0, J₂ = 2.5 H-4), 7.12 (td, 1H, J₁ = 7.4, J₂ = 1.5, H-5). 13C NMR (50 MHz, DMSO-d₆) δ: 161.1 (d, J₁ = 236 Hz, 6), 156.4 (6), 153.9 (2), 148.7 (2’), 148.6 (3a), 2x132.6 (7a, 5’), 131.0 (4’), 130.9 (3’), 124.3 (6’), 123.8 (1’), 111.0 (d, J₂ = 25 Hz, 5), 110.5 (5), 101.8, (d, J₂ = 25 Hz, 7) 101.3 (7). Anal. Calcd. for C₁₃H₈FN₃O₂ (MW: 257.22): C, 60.70; H, 3.13; N, 16.34. Found: C, 60.82; H, 3.23; N, 15.99.

**6-Bromo-2-(2’-nitrophenyl)-1H-benzo[d]imidazole (1c).** Prepared from 4-bromo-1,2-phenylenediamine (500 mg, 2.67 mmol) and 2-nitrobenzaldehyde (403 mg, 2.67 mmol). Yield = 64%; mp: 147 – 149 °C (Ethanol); IR (KBr) cm⁻¹: 3423 (NH), 1526, 1349 (NO₂), 1H NMR (200 MHz, DMSO-d₆) δ: 13.24 (s, 1H, NH), 8.02 (d, 1H, J = 8.0, H-3’), 7.93 (d, 1H, J = 7.7, H-6’), 7.84 (td, 1H, J₁ = 7.5, J₂ = 1.1, H-5’), 7.74 (td, 1H, J₁ = 7.8, J₂ = 1.3, H-4’), 7.65 (s, 1H, H-7), 7.59 (d, 1H, J = 8.5, H-4), 7.23 (dd, 1H, J₁ = 8.5, J₂ = 1.8, H-5). 13C NMR (50 MHz, DMSO-d₆) δ: 149.4 (2), 149.3 (2’), 2x 138.1 (3a, 7a), 133.4 (5’), 131.7 (4’), 131.6 (6’), 124.9 (3’), 2x 124.4 (5, 1’), 123.3 (4), 2x 117.3 (6, 7). Anal. Calcd. for C₁₃H₈BrN₃O₂ (MW: 318.13): C, 49.08; H, 2.53; N, 13.21. Found: C, 49.18; H, 2.69; N, 13.48.

**6-Chloro-2-(2’-nitrophenyl)-1H-benzo[d]imidazole (1d).** Prepared from 4-chloro-1,2-phenylenediamine (500 mg, 3.51 mmol) and 2-nitrobenzaldehyde (518 mg, 3.51 mmol). Yield = 72%; mp: 108–109 °C (Ethanol); IR (KBr) cm⁻¹: 3422 (NH), 1526, 1349 (NO₂), 1H NMR (200 MHz, DMSO-d₆) δ: 13.15 (1H, s, NH), 8.02 (d, 1H, d, J = 8.0, H-3’), 7.93 (1H, d, J = 7.6, H-6’), 7.84 (1H, t, J = 7.5, H-5’), 7.79 (1H, s, H-7), 7.75 (1H, t, J₁ = 8.0, J₂ = 1.1, H-4’), 7.55 (1H, d, J = 8.6, H-4), 7.35 (1H, dd, J₁ = 8.5, J₂ = 1.6, H-5). 13C NMR (50 MHz, DMSO-d₆) δ: 149.4 (2), 149.2 (2’), 2x 138.1 (3a, 7a), 133.3 (5’), 131.7 (4’), 131.6 (6’), 125.9 (3’), 124.9 (6’), 2x 124.4 (5, 1’), 2 x 115.2 (4, 7). Anal. Calcd. for C₁₃H₈ClN₃O₂ (MW: 273.67): C, 57.05; H, 2.95; N, 15.35. Found: C, 57.40; H, 2.65; N, 15.24.
5,6-Dimethyl-2-(2'-nitrophenyl)-1H-benzo[d]imidazole (1e). Prepared from 4,5-dimethyl-1,2-phenylenediamine (500 mg, 3.67 mmol) and 2-nitrobenzaldehyde (555 mg, 3.67 mmol). Yield = 91%; mp: 190–191°C (Ethanol); IR (KBr) cm⁻¹: 3395 (NH), 1526 (NO₂), 1347 (NO₂), 1H NMR (200 MHz-DMSO-d₆) δ: 12.93 (s, 1H, NH), 7.93 (t, 2H, J = 8.6, H-3’,6’), 7.79 (t, 1H, J = 7.4, H-5’), 7.67 (t, 1H, J = 7.6, H-4’), 7.39 (s, 1H, H-7), 7.28 (s, 1H, H-4), 2.32 (s, 6H, 2x CH₃). 13C NMR (50 MHz, DMSO-d₆) δ: 149.4 (2), 146.7 (2’), 138.1 (3a), 132.9 (7a), 131.1 (5’), 131.0 (3’), 2 x 124.9 (5, 6), 124.6 (1’), 2 x 119.7 (4, 4’), 112.0 (7), 2x20.5 (8, 9). Anal Calcd for C₁₅H₁₃N₃O₂ (MW: 267.28): C, 67.40; H, 4.90; N, 15.72. Found: C, 67.21; H, 4.96; N, 15.60.

General synthetic procedure for 2-(1H-benzimidazol-2-yl) aniline derivatives 2a-e
Iron powder (500 mg, 9 mmol) is added to a solution of the corresponding benzimidazole (1 equiv.) in a solution of HCl (concd.):EtOH:H₂O (0.25:1:1) (50 mL). The mixture is stirred at room temperature by 15 minutes and then neutralized with solid NaHCO₃. The crude is extracted with ethyl acetate (25 mLx3), evaporated under vacuum and dried with anhydrous Na₂SO₄ to yield the reduced derivative. Compound 2a has been previously described.21

2-(6'-Fluoro-1H-benzimidazol-2'-yl)aniline (2b). Prepared from 6-fluoro-2-(2-nitrophenyl)-1H-benzo[d]imidazole (385 mg, 1.50 mmol) and Fe⁰ (500 mg, 9 mmol). Yield: 55%; mp: 179–181 ºC (Ethanol); IR (KBr) cm⁻¹: 3382 (NH), 3178 (NH₂), 3153 (NH₂). 1H NMR (200 MHz, DMSO-d₆) δ: 12.37 (b.s., 1H, NH), 7.72 (dd, 1H, J₁ = 7.9, J₂ = 1.2, H-4’), 7.41 (dd, 1H, J₁ = 8.0, J₂ = 1.2 H-7´), 7.05 (d, 1H, J = 7.5, H-3), 6.87 (t, 1H, J₁ = 7.2, J₂ = 2.5, H-5), 6.76 (d, 1H, J = 7.9, H-6), 6.60 (t, 1H, J = 7.7, H-4), 3.24 (b.s., 2H, NH₂). 13C NMR (50 MHz, DMSO-d₆) δ: 161.7 (d, J₁ = 260Hz, 6’), 156.5 (6’), 151.8 (2’), 2 x 147.6 (3a’, 7a’), 130.0 (4), 126.9 (6), 2 x 123.1 (5, 4’), 116.0 (7’), 115.0 (3), 110.9 (d, J₂ = 37 Hz, 5’), 110.2 (5’), 102.8(d, J₂ = 37 Hz, 7’), 102.1(7’) Anal. Calcd for C₁₃H₁₀FN₃ (MW: 227.24): C, 68.71; H, 4.44; N, 18.49. Found: C, 68.35; H, 4.48; N, 18.11

2-(6'-Bromo-1H-benzimidazol-2'-yl)aniline (2c). Prepared from 6-bromo-2-(2-nitrophenyl)-1H-benzo[d]imidazole (420 mg, 1.32 mmol) and Fe⁰ (500 mg, 9 mmol). Yield: 51%; mp: 153–155 ºC (Ethanol); IR (KBr) cm⁻¹: 3422 (NH₂), 3383 (NH₂), 1618 (C-N). 1H NMR (200 MHz, DMSO-d₆) δ: 12.79 (b.s., 1H, NH), 7.82 (d, 1H, J = 7.8, H-5’), 7.63 (s, 1H, H-7’), 7.35 (m, 2H, H-3´,4´), 7.17 (t, 3H, J = 7.3, H-5 and NH₂), 6.84 (d, 1H, J = 8.3, H-6), 6.65 (t, 1H, J = 7.5 and H-4). 13C NMR (50 MHz DMSO-d₆) δ: 148.1 (2’), 146.8 (2), 2x130.8 (3a’, 7a’), 127.2 (4), 124.9 (5’), 120.4 (6), 116.2 (4’), 2 x 115.2 (5, 7’), 113.4 (1), 112.4 (3), 109.4 (6’). Anal. Calcd. for C₁₃H₁₀BrN₃ (MW: 288.14): C, 54.19; H, 3.50; N, 14.58. Found: C, 54.46; H, 3.71; N, 14.29.

2-(6'-Chloro-1H-benzimidazol-2'-yl)aniline (2d). Prepared from 6-chloro-2-(2-nitrophenyl)-1H-benzo[d]imidazole (450 mg, 1.64 mmol) and Fe⁰ (500 mg, 9 mmol). Yield: 58%; mp: 165–167 ºC (Ethanol); IR (KBr) cm⁻¹: 3372 (NH₂), 3324 (NH₂), 1617 (C-N). 1H NMR (200 MHz, DMSO-d₆) δ: 12.47 (b.s., 1H, NH), 7.72 (d, 1H, J = 8.5, H-7’), 7.45 (d, 1H, J = 8.3, H-4’), 7.33 (d, 1H, J = 8.7, H-5’), 7.19 (d, 1H, J = 8.8, H-3), 7.06 (t, 1H, J₁ = 8.1, J₂ = 1.4, H-5), 6.79 (b.s, 2H, NH₂), 6.76 (d, 1H, J = 8.2, H-6’), 6.60 (t, 1H, J₁ = 8.1, J₂ = 1.1, H-4). 13C NMR (50 MHz DMSO-d₆) δ: 147.7 (2’), 2x130.2 (3a’, 7a’), 127.1 (2), 124.5 (4), 120.4 (5’), 119.2 (4’), 116.1
2-(5',6'-Dimethyl-1H-benzimidazol-2'-yl)aniline (2e). Prepared from 5,6-dimethyl-2-(2-nitrophenyl)-1H-benzo[d]imidazole (510 mg, 1.91 mmol) and Fe(0) (500 mg, 9 mmol). Yield: 67%; mp: 183–185 ºC (Ethanol); IR (KBr) cm\(^{-1}\): 3360 (NH\(_2\)), 3336 (NH\(_2\)), 1623 (C-N). \(^1\)H NMR (200 MHz, DMSO-\(d_6\)) \(\delta\): 12.31 (1H, s, NH), 7.79 (d, J\(_1\) = 7.9, J\(_2\) = 1.4, H-3), 7.40 (1H, s, H-7'), 7.25 (1H, s, H-4'), 7.22-7.14 (b.s, 2H, NH\(_2\)), 7.10 (dd, J\(_1\) = 7.0, J\(_2\) = 1.5, H-5), 6.80 (dd, 1H, J\(_1\) = 8.2, J\(_2\) = 1.1, H-6), 6.63 (t, 1H, J\(_1\) = 7.0, J\(_2\) = 1.2, H-4), 2.32 (s, 6H, 2x CH\(_3\)). \(^1\)C NMR (50 MHz DMSO-\(d_6\)) \(\delta\): 168.5 (2'), 142.4 (2), 2x 136.6 (3a', 7a''), 2x 132.0 (5', 6'), 130.5 (4), 125.1 (6), 122.5 (5), 121.55 (1), 2x 119.7 (4', 7'), 110.5 (3), 20.6 (8), 20.4 (9). Anal. Calcd. for C\(_{15}\)H\(_{15}\)N\(_3\) (MW: 237.30): C, 75.92; H, 6.37; N, 17.71. Found: C, 76.17; H, 6.67; N, 17.16.

**General synthetic procedure for 5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives 3a-e**

A solution of 2-bromoacetyl bromide (1.5 equiv.) in anhydrous THF (30 mL) containing Na\(_2\)CO\(_3\) (2 equiv.) and the corresponding 2-(1H-benzimidazol-2-yl) aniline derivative (1 equiv.) is heated under microwave irradiation (300W). The reaction mixture is then filtered and the solvent removed under vacuum. The obtained crude is precipitated in an ethanol-water (1:10) mixture.

**5H-Benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one (3a).** Prepared from 2-(1H-benzimidazol-2-yl)aniline (400 mg, 1.68 mmol) and bromoacetyl bromide (508 mg, 2.52 mmol). Yield: 70%; mp: 260–262 ºC; IR (KBr) cm \(^{-1}\): 3215 (NH), 1686 (C=O); \(^1\)H NMR (200 MHz, DMSO-\(d_6\)) \(\delta\): 10.67 (s, 1H, NH), 8.10 (d, J\(_1\) = 7.8, H-12), 7.84 (d, 1H, J = 8.3, H-9), 7.75 (d, 1H, J = 7.2, H-1), 7.59 (t, 1H, J = 8.4, H-11), 7.37 (t, 1H, J = 7.5, H-10), 7.30 (m, 3H, H-2,3,4), 4.96 (s, 2H, CH\(_2\)). \(^1\)C NMR (50 MHz DMSO-\(d_6\)) \(\delta\): 168.4 (6), 151.0 (13), 143.7 (4a), 136.8 (8a), 135.2 (12a), 131.8 (3), 130.6 (1), 125.2 (2), 123.1 (11), 123.0 (10), 122.5 (4), 121.3 (12), 119.7 (13a), 110.6 (9), 47.3 (7). Anal. Calcd. for C\(_{15}\)H\(_{11}\)N\(_3\)O (MW: 249.27): C, 72.28; H, 4.45; N, 16.86; Found: C, 71.90; H, 4.97; N, 16.63.

**10-Fluoro-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one (3b).** Prepared from 2-(6-fluoro-1H-benzo[d]imidazol-2-yl)aniline (310 mg, 1.36 mmol) and bromoacetyl bromide (412 mg, 2.04 mmol). Yield: 57%; mp: 239–242 ºC; IR (KBr) cm \(^{-1}\): 3245 (NH), 1681 (C=O); \(^1\)H NMR (200 MHz, DMSO-\(d_6\)) \(\delta\): 10.67 (s, 1H, NH), 8.10 (d, 1H, J = 7.8, H-12), 7.84 (d, 1H, J = 8.3, H-9), 7.75 (d, 1H, J = 7.2, H-1), 7.59 (t, 1H, J = 8.4, H-11), 7.37 (t, 1H, J = 7.5, H-10), 7.30 (m, 3H, H-2,3,4), 4.96 (s, 2H, CH\(_2\)). \(^1\)C NMR (50 MHz DMSO-\(d_6\)) \(\delta\): 168.4 (6), 151.0 (13), 143.7 (4a), 136.8 (8a), 135.2 (12a), 131.8 (3), 130.6 (1), 125.2 (2), 123.1 (11), 123.0 (10), 122.5 (4), 121.3 (12), 119.7 (13a), 110.6 (9), 47.3 (7). Anal. Calcd. for C\(_{15}\)H\(_{10}\)FN\(_3\)O (MW: 267.26): C, 72.28; H, 4.45; N, 16.86; Found: C, 71.90; H, 4.97; N, 16.63.

**10-Bromo-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one (3c).** Prepared from 2-(6-bromo-1H-benzimidazol-2-yl)aniline (350 mg, 1.25 mmol) and bromoacetyl bromide (368 mg, 1.82 mmol). Yield: 55%; mp: 279–281 ºC; IR (KBr) cm \(^{-1}\): 3420 (NH), 1686 (C=O); \(^1\)H NMR
(200 MHz, DMSO-$d_6$) $\delta$: 10.57 (s, 1H, NH), 8.09 (d, 1H, $J = 8.0$, H-12), 7.79 (d, 1H, $J = 8.1$, H-11), 7.70 (s, 1H, H-9), 7.50 (m, 2H, H-1,3), 7.42 (t, 1H, $J = 7.7$, H-2), 7.46 (d, 1H, $J = 7.3$, H-4); 4.74 (s, 2H, CH$_2$). $^{13}$C NMR (50 MHz DMSO-$d_6$) $\delta$: 167.0 (6), 137.0 (13), 131.3 (4a), 129.9 (12a), 126.5 (8a), 126.3 (3), 124.4 (1), 123.9 (11), 121.8 (2), 120.9 (12), 119.8 (4), 116.0 (10), 113.0 (13a), 110.7 (9), 46.9 (7). Anal. Calcd. for C$_{15}$H$_{10}$BrN$_3$O (MW: 328.16): C, 54.90; H, 3.07; N, 12.80; Found: C, 54.80; H, 3.06; N, 12.61.

10-Chloro-5$H$-benzimidazo[1,2-$d$][1,4]benzodiazepin-6(7$H$)-one (3d). Prepared from 2-(6-chloro-1$H$-benzimidazol-2-yl)aniline (530 mg, 2.17 mmol) and bromoacetyl bromide (658 mg, 3.26 mmol). Yield: 48%; mp: 309–311 ºC; IR (KBr) cm$^{-1}$: 3200 (NH), 1692 (C=O); $^1$H NMR (200 MHz, DMSO-$d_6$) $\delta$: 10.67 (s, 1H, NH), 8.05 (d, 1H, $J = 7.4$, H-12), 7.91 (s 1H, H-9), 7.80 (d, 1H, $J = 7.6$, H-11), 7.70 (d, 1H, $J = 7.6$, H-1), 7.60 (td, 1H, $J_1 = 7.6$, $J_2 = 1.2$, H-2), 7.51 (m, 1H, H-3), 7.49 (dd, 1H, $J_1 = 7.9$, $J_2 = 2.1$, H-4), 4.96 (s, 2H, 5-CH$_2$). $^{13}$C NMR (50 MHz DMSO-$d_6$) $\delta$: 167.5 (6), 136.5 (13), 131.8 (4a), 130.1 (12a), 125.8 (3), 125.5 (1), 124.6 (11), 122.0 (2), 121.2(12), 120.3(4), 119.6 (4), 115.2 (10), 113.5 (13a), 112.2 (9), 47.1 (7). Anal. Calcd. for C$_{15}$H$_{10}$ClN$_3$O (MW: 283.71); C, 63.50; H, 3.55; N, 14.81; Found: C, 63.76; H, 3.76; N, 14.55.

10,11-Dimethyl-5$H$-benzimidazo[1,2-$d$][1,4]benzodiazepin-6(7$H$)-one (3e). Prepared from 2-(5,6-dimethyl-1$H$-benzimidazol-2-yl)aniline (425 mg, 1.79 mmol) and bromoacetyl bromide (542 mg, 2.69 mmol). Yield: 50%; mp: 286–288 ºC; IR (KBr) cm$^{-1}$: 3206 (NH), 1677 (C=O); $^1$H NMR (200 MHz, DMSO-$d_6$) $\delta$: 10.55 (s, 1H, NH), 8.02 (d, 1H, $J = 7.7$, H-12), 7.55 (s, 1H, H-9), 7.51 (td, 1H, $J_1 = 8.0$, $J_2 = 1.2$, H-3), 7.47 (s, 1H, H-12), 7.30 (t, 1H, $J = 7.6$, H-2), 7.24 (d, 1H, $J = 8.1$, H-4), 4.86 (s, 2H, CH$_2$), 2.32 (s, 3H, CH$_3$), 2.22 (s, 3H, CH$_3$). $^{13}$C NMR (50 MHz, DMSO-$d_6$) $\delta$: 168.5 (6), 142.4 (13a), 136.6 (4a), 133.8 (12a), 132.0 (8a), 2x 131.4 (10, 11), 130.5 (3), 2x 125.1 (1, 2), 122.5 (4), 121.5 (12), 119.7 (9), 110.5 (13a), 47.3 (7), 20.6 (15), 20.4 (14). Anal. Calcd. for C$_{17}$H$_{15}$N$_3$O (MW: 277.32); C, 73.63; H, 5.45; N, 15.15; Found: C, 73.90; H, 5.11; N, 14.81.

Acknowledgements

This project was supported by VRAID (Grant Nº 01/2008).

References

1. Elliott, J. M.; Carlson, E. J.; Chicchi, G. G.; Dirat, O.; Dominguez, M.; Gerhard, U.; Jelley, R.; Jones, A. B.; Kurtz, M. M.; Tsao, K. I.; Wheeldon, A. Bioorg Med. Chem. Lett. 2006, 16, 11, 2932.
2. Conejo-García, A.; Núñez, M.; Díaz-Gavilán, M.; Cruz-López, O.; Gallo, M. A.; Espinosa, A.; Campos, J. M. Expert Opinion on Drug Discovery 2008, 3, 10, 1223.
3. Fukinaga, M.; Ishizawa, K.; Kamei, C. Pharmacology 1998, 57, 233.
4. Hurley, L. H.; Reck, T.; Thurston, D. E.; Langley, D. R.; Holden, K. G.; Hertzberg, R. P.; Hoover, J. R.; Gallagher, G. Jr.; Faucette, L. F.; Mong, S. M. Chem. Res. Toxicol. 1988, 1, 5, 258.

5. Kumar, R.; Lown, J. W. Oncology Research 2003, 13, 4, 221.

6. Baraldi, P. G.; Leoni, A.; Cacciari, B.; Manfredini, S.; Simoni, D.; Bergomi, M.; Menta, E. Eur. J. Med. Chem. 1994, 37, 25, 4329.

7. Wang, L.; Sullivan, G. M.; Hexamer, L. A.; Hasvold, L. A.; Thalji, R.; Przytulinska, M.; Tao, Z.; Li, G.; Chen, Z.; Xiao, Z.; Gu, W.; Xue, J.; Bui, M.; Merta, P.; Kovar, P.; Bouska, J. J.; Zhang, H.; Park, Ch.; Stewart, K.; Sham, H. L.; Sowin, T. J.; Rosenberg, S. H.; Lin, N. J. Med. Chem. 2007, 50, 4162.

8. Tanious, F. A.; Laine, W.; Peixoto, P.; Bailly, C.; Goodwin, K. D.; Lewis, M. A.; Long, E. C.; Georgiadis, M. M.; Tidwell, R. R.; Wilson, D. W. Biochemistry 2007, 46, 6944.

9. Starcecic, K.; Krajl, M.; Ester, K.; Sabol, I.; Grce, M.; Paviě, K.; Karmisnski-Zamola, G., Bioorg. Med. Chem. 2007, 15, 4419.

10. Ramla, M. M.; Omar, M. A.; Tokuda, H.; El Diwani, H. I. Bioorg. Med. Chem. 2007, 15, 6489.

11. Hoang, H.; LaBarbera, D. V.; Mohammed, K. A.; Ireland, C. M.; Skibo, E. B. J. Med. Chem. 2007, 50, 4561.

12. Cachoux, F.; Isarno, T.; Wartmann, M.; Altmann, K. H. ChemBioChem 2006, 7, 54.

13. Xiangming H., Huiqiang, M., Yulu, W. Arkivoc 2007, (xiii), 150.

14. Duncan, R. L.; Helseley, C. H.; Boswell, R. F. J. Heterocycl. Chem. 1973, 10, 65.

15. Cherkaoui, O.; Cherkaoui, M. Z.; Essassi, E. M., Zniber, R. Synth. Commun. 1995, 25, 7, 1027.

16. Skalitzky, D. J.; Markovits, J. T.; Maegley, K. A.; Ekker, A.; Yu, X. H.; Hostomsky, Z.; Webber, S. E.; Eastman, B. W.; Almassy, R.; Li, J.; Curtin, N. J.; Newell, D. R.; Calvert, A. H.; Griffin, R. J.; Golding, B. T. J. Med. Chem. 2003, 16, 46, 210.

17. Pessoa-Mahana, H.; Salazar, R. C.; Pessoa-Mahana, C. D.; Valderrama, J.; Sáez, E. Araya-Maturana, R. Synthesis 2004, 3, 446.

18. Larhed, M.; Hallberg, A. DDT 2001, 6, 8, 406.

19. Feliu, L.; Font, D.; Soley, R.; Tailhades, J.; Martinez, J.; Amblard, M. Arkivoc 2007, (iv), 65.

20. Khalid, B., Andrq, L., Mohamed, S. Tetrahedron 1998, 54, 8055

21. Bahekar, R., Rao, A. Indian Journal of Pharmaceutical Sciences 2000, 62(1), 41.